NASDAQ · KYMRHealthcareBiotechnology

Kymera Therapeutics financials

$110.51−1.33%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
Revenue$39.2M$47.1M$78.6M$46.8M$72.8M$34.0M
Gross profit$39.2M$47.1M$78.6M$46.8M$72.8M$34.0M
Gross margin100.0%100.0%100.0%100.0%100.0%100.0%
Operating income-$349.4M-$261.6M-$165.5M-$161.3M-$100.5M-$46.3M
Net income-$311.4M-$223.9M-$147.0M-$154.8M-$100.2M-$54.6M
Net margin−794.0%−475.6%−187.0%−330.6%−137.6%−160.6%
Diluted EPS$-3.69$-2.98$-2.52$-2.87$-2.09$-3.15
EBITDA-$337.2M-$249.3M-$162.0M-$161.3M-$98.1M-$44.5M
Operating cash flow-$232.9M-$194.5M-$102.8M-$153.1M-$128.9M$88.1M
Free cash flow-$234.3M-$207.3M-$137.3M-$155.9M-$130.5M$79.0M
Diluted shares84.5M75.0M58.4M53.9M48.0M17.3M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$357.0M$120.3M$110.0M$68.4M$48.0M$31.0M
Short-term investments$491.3M$368.5M$264.9M$338.8M$394.4M$265.2M
Total debt$3.3M$3.7M$2.6M$2.7M$2.3M$1.3M
Total assets$1.74B$978.0M$575.8M$603.1M$605.9M$487.2M
Total liabilities$163.1M$142.4M$180.8M$113.0M$146.3M$203.3M
Shareholders' equity$1.58B$835.6M$395.0M$490.2M$459.6M$283.9M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology